Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected]

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Histone deacetylases (HDACs) are enzymes involved in gene regulation and cellular processes.
• HDAC6 is a specific HDAC isoform implicated in cancer progression and metastasis.
• Targeting HDAC6 offers a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

• To develop and characterize a novel, potent, and selective inhibitor of HDAC6.
• To evaluate the efficacy of the HDAC6 inhibitor in blocking the growth of normal and transformed cells.
• To compare the anticancer activity of the HDAC6 inhibitor with paclitaxel in vivo.

Main Methods:

• Synthesis and characterization of a novel small molecule inhibitor targeting HDAC6.
• In vitro cell proliferation assays using normal and cancer cell lines.
• In vivo studies in tumor-bearing mouse models to assess anticancer efficacy.

Main Results:

• The developed compound is a potent and selective inhibitor of HDAC6.
• HDAC6 inhibition effectively blocks the growth of both normal and transformed cells.
• Normal cells treated with the inhibitor do not undergo cell death.
• The HDAC6 inhibitor demonstrates anticancer activity in vivo, comparable to paclitaxel.

Conclusions:

• Selective HDAC6 inhibition is a promising strategy for cancer therapy.
• This novel HDAC6 inhibitor exhibits potent anticancer effects with a favorable safety profile in preclinical studies.
• Further investigation of this HDAC6 inhibitor for clinical application is warranted.